Dr hab. Marcin Waligóra, prof. UJ
fot. Jacek Taran
Kierownik Zakładu Bioetyki
Prodziekan ds. Rozwoju Naukowego na Wydziale Nauk o Zdrowiu Uniwersytetu Jagiellońskiego. Przewodniczący Rady Dyscypliny Nauki o Zdrowiu. Harvard Fulbrighter (Harvard Medical School Center for Bioethics 2017/18).
Zajmuje się etyką badań naukowych w biomedycynie. Kieruje projektami badawczymi finansowanymi przez Komisję Europejską i NCN, realizowanymi przez zespół Research Ethics in Medicine Study Group (REMEDY).
Stypendysta Komisji Fulbrighta (Senior Award, 2017), MNiSW (2014), the NIH-Fogarty (2009), the Nippon Foundation (2006), Florentyny Kogutowskiej (2005), The International Academy of Philosophy (2005).
Studiował na Uniwersytecie Jagiellońskim (doktorat w zakresie filozofii, 2007) oraz w International Academy of Philosophy w Santiago de Chile (2005). Ukończył także program dotyczący etyki badań naukowych finansowany przez the NIH (2012) oraz the Leadership Academy for Poland (2018).
Wybrane publikacje:
- Buedo P, Odziemczyk I, Perek-Białas J, Waligora M. How to embed ethics into laboratory research. Account Res. 2023 Jan 17:1-20, DOI: 10.1080/08989621.2023.2165916
- Hutchinson N, Klas K, Carlisle BG, Polak M, Kimmelman J, Waligora M. Competition for recruitment in SARS-CoV-2 Trials in the United States: a longitudinal cohort analysis. BMC Res Notes 15, 368 (2022). doi.org/10.1186/s13104-022-06263-1
- Hutchinson N, Klas K, Carlisle BG, Kimmelman J, Waligora M. How informative were early SARS-CoV-2 treatment and prevention trials? a longitudinal cohort analysis of trials registered on ClinicalTrials.gov. PLoS One. 2022;17(1):e0262114.
- Waligora M., & Klas K. (2022). Masking. In B. Frey (Ed.), The SAGE encyclopedia of research design (Vol. 1, pp. 860-861). SAGE Publications, Inc.
- Strzebonska K, Blukacz M, Wasylewski MT, Polak M, Gyawali B, Waligora M. Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis. BMC Med. 2022; 20:219. doi: 10.1186/s12916-022-02420-2
- Strzebonska K, Wasylewski MT, Zaborowska L, Polak M, Slugocka E, Stras J, Blukacz M, Gyawali B, Waligora M. Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis. Target Oncol. 2021; 16(4):415-424. doi:10.1007/s11523-021-00822-5
- Wasylewski MT, Strzebonska K, Koperny M, Polak M, Kimmelman J, Waligora M (2020), Clinical development success rates and social value of pediatric Phase 1 trials in oncology, PLoS ONE 15(6): e0234911. doi: 10.1371/journal.pone.0234911
- Strzebonska K, Wasylewski MT, Zaborowska L, Riedel N, Wieschowski S, Strech D, Waligora M. Results dissemination of registered clinical trials across Polish academic institutions: a cross-sectional analysis, BMJ Open. 2020 Jan 22;10(1):e034666. doi: 10.1136/bmjopen-2019-034666
- Strzebonska K, Waligora M, Umbrella and basket trials in oncology: ethical challenges, BMC Med Ethics. 2019 Aug 23;20(1):58. doi: 10.1186/s12910-019-0395-5
- Strzebonska K, Waligora M, Underestimation of Harms in Phase I Trials, The Journal of Law, Medicine & Ethics, 2019 Jun;47(2):334-335. doi: 10.1177/1073110519857290
- Kimmelman J, Waligora M, Fernandez Lynch H, Participants Protection in Phase1 Pediatric Cancer Trials, JAMA Pediatrics 2019;173(1):8-9. doi:10.1001/jamapediatrics.2018.3629
- Waligora M, Bala MM, Koperny M, Wasylewski MT, Strzebonska K, Jaeschke RR, Wozniak A, Piasecki J, Sliwka A, Mitus JW, Polak M, Nowis D, Fergusson D, Kimmelman J, Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis, PLoS Med 15(2): e1002505. doi: 10.1371/journal.pmed.1002505
- Waligora M, Strzebonska K, Wasylewski MT, Neither the Harm Principle nor the Best Interest Standard Should Be Applied to Pediatric Research, American Journal of Bioethics, 2018 Aug;18(8):72-74. doi: 10.1080/15265161.2018.1485762
- Piasecki J, Dranseika V, Waligora M, Should Epidemiological Studies Be Subject to Ethics Review?, Public Health Ethics, 2017, phx016. doi: 10.1093/phe/phx016
- Dranseika V, Gefenas E, Waligora M, Broadening the “Infrastructure Effect”: Lessons from the Early Development of Research Ethics in Eastern Europe, The American Journal of Bioethics, 2016 Jun; 16(6):26-8. doi: 10.1080/15265161.2016.1170243
- Mezinska S, Kakuk P, Mijaljica G, Waligóra M, O’Mathúna DP, Research in disaster settings: a systematic qualitative review of ethical guidelines, BMC Medical Ethics, 2016, 17:62. doi: 10.1186/s12910-016-0148-7
- Waligora M, Rozynska J, Piasecki J, Child’s objection to non-beneficial research: capacity and distress based models, Medicine, Health Care and Philosophy 2016 Mar;19(1):65-70. doi: 10.1007/s11019-015-9643-8
- M. Waligora, V. Dranseika, J. Piasecki, Child’s assent in research: Age threshold or personalisation?, BMC Medical Ethics 2014, 15:44. doi: 10.1186/1472-6939-15-44
- M. Waligora Failures in Clinical Trials in the European Union: Lessons from the Polish Experience, Science and Engineering Ethics 2013 Sep; 19(3):1087-98. doi:10.1007/s11948-012-9400-9
Więcej informacji na stronie remedy.edu.pl
